Targeting C-reactive protein for the treatment of cardiovascular disease.
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Complement-mediated inflammation exacerbates the tissue injury of ischaemic necrosis in heart attacks and strokes, the most common causes of death in developed countries. Large infarct size increases immediate morbidity and mortality and, in survivors of the acute event, larger non-functional scars adversely affect long-term prognosis. There is thus an important unmet medical need for new cardioprotective and neuroprotective treatments. We have previously shown that human C-reactive protein (CRP), the classical acute-phase protein that binds to ligands exposed in damaged tissue and then activates complement, increases myocardial and cerebral infarct size in rats subjected to coronary or cerebral artery ligation, respectively. Rat CRP does not activate rat complement, whereas human CRP activates both rat and human complement. Administration of human CRP to rats is thus an excellent model for the actions of endogenous human CRP. Here we report the design, synthesis and efficacy of 1,6-bis(phosphocholine)-hexane as a specific small-molecule inhibitor of CRP. Five molecules of this palindromic compound are bound by two pentameric CRP molecules, crosslinking and occluding the ligand-binding B-face of CRP and blocking its functions. Administration of 1,6-bis(phosphocholine)-hexane to rats undergoing acute myocardial infarction abrogated the increase in infarct size and cardiac dysfunction produced by injection of human CRP. Therapeutic inhibition of CRP is thus a promising new approach to cardioprotection in acute myocardial infarction, and may also provide neuroprotection in stroke. Potential wider applications include other inflammatory, infective and tissue-damaging conditions characterized by increased CRP production, in which binding of CRP to exposed ligands in damaged cells may lead to complement-mediated exacerbation of tissue injury.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Heuristics may lead to bias or predictable and systematic cognitive errors, as described in Table 2.16,35”
From Artificial Intelligence and Surgical Decision-making. (2020) · cites this paper as [54]
Citations
Cites
PROCHECK: a program to check the stereochemical quality of protein structures
Laskowski, R. A., MacArthur, M. W., Moss, D. S., & Thornton, J. M. (1993) · Journal of Applied Crystallography · doi:10.1107/s0021889892009944 · Cited by 24,581
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination
Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., et al. (1998) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444998003254 · Cited by 15,715
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,742
MOLREP: an Automated Program for Molecular Replacement
Vagin, A., & Teplyakov, A. (1997) · Journal of Applied Crystallography · doi:10.1107/s0021889897006766 · Cited by 4,714
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18921 · Cited by 3,503
Self-citationWHAT IF: A molecular modeling and drug design program
Vriend, G. (1990) · Journal of Molecular Graphics · doi:10.1016/0263-7855(90)80070-v · Cited by 3,469
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318921 · Cited by 3,436
Self-citationThe integration of macromolecular diffraction data
Leslie, A. G. W. (2006) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444905039107 · Cited by 1,341
The physiological structure of human C-reactive protein and its complex with phosphocholine
Thompson, D., Pepys, M. B., & Wood, S. P. (1999) · Structure · doi:10.1016/s0969-2126(99)80023-9 · Cited by 818
Self-citation
Cited by
Items 201–300 of 670
C-Reactive Protein and Coronary Disease: Is There a Causal Link?
Danesh, J. N., & Pepys, M. B. (2009) · Circulation · doi:10.1161/circulationaha.109.907212 · Cited by 61
Self-citationCRP CHD Genetics Collaboration (2008) · European Journal of Epidemiology · doi:10.1007/s10654-008-9249-z · Cited by 59
“Selective CRPlowering agents have been invented and are under development, particularly to determine whether anti-CRP agents might have a role in reducing tissue damage very soon after a myocardial infarction (MI) when there are massive, shortterm spikes in CRP levels [15].”
BackgroundCaprio, V., Badimon, L., Di Napoli, M., Fang, W.-H., Ferris, G. R., Guo, B., Iemma, R. S., Liu, D., Zeinolabediny, Y., & Slevin, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01089 · Cited by 52
“The only small molecule demonstrated to inhibit dissociation of pCRP to mCRP is the bis-phosphocholine dimer 1,6-bis (phosphocholine)-hexane (bis(PC)-H) 9 (22).”
BackgroundExtracellular vesicles are associated with C-reactive protein in sepsis
Fendl, B., Weiss, R., Eichhorn, T., Linsberger, I., Afonyushkin, T., Puhm, F., Binder, C. J., Fischer, M. B., & Weber, V. (2021) · Scientific Reports · doi:10.1038/s41598-021-86489-4 · Cited by 58
Monomeric C-Reactive Protein in Atherosclerotic Cardiovascular Disease: Advances and Perspectives
Melnikov, I., Kozlov, S. G., Saburova, O., Avtaeva, Y., Guria, K. G., & Ахнафович, Г. З. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032079 · Cited by 59
LOX-1: a multiligand receptor at the crossroads of response to danger signals
Sawamura, T., Kakino, A., & Fujita, Y. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32835688e4 · Cited by 55
“They further developed a small chemical compound which blocks CRP-induced complement activation by covalently bridge complement binding the surface of two CRP molecules [39].”
BackgroundMarkers of Inflammation and Risk of Coronary Heart Disease
Sarwar, N., Thompson, A. J., & Di Angelantonio, E. (2009) · Disease Markers · doi:10.1155/2009/851962 · Cited by 43
The Role of NLRP3 Inflammasome in Obesity and PCOS—A Systematic Review and Meta-Analysis
Alenezi, S. A., Khan, R. N., Snell, L., Aboeldalyl, S., & Amer, S. A. K. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310976 · Cited by 60
Inflammatory biomarkers and coronary heart disease: from bench to bedside and back
Biasillo, G., Leo, M., Bona, R. D., & Biasucci, L. M. (2010) · Internal and Emergency Medicine · doi:10.1007/s11739-010-0361-1 · Cited by 60
“[18],”
Panax notoginseng Saponins Attenuate Atherogenesis Accelerated by Zymosan in Rabbits
Liu, Y., Zhang, H., Jia, Y., & Li, X. (2010) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.33.1324 · Cited by 54
Belcaro, G., Cesarone, M. R., Errichi, S., Zulli, C., Errichi, B. M., Vinciguerra, G., Ledda, A., Renzo, A. D., Stuard, S., Dugall, M., et al. (2008) · Redox Report · doi:10.1179/135100008x309019 · Cited by 53
Zeller, J., Shing, K. S. C. T., Nero, T. L., McFadyen, J. D., Krippner, G. Y., Bogner, B., Kreuzaler, S., Kiefer, J., Horner, V. K., Braig, D., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202216236 · Cited by 53
“The use of external administered human CRP in various rat models of acute inflammation represents the established standard of both in vivo and ex vivo studies of the inflammatory profile of human CRP (Gill et al , 2004; Pepys et al , 2006; Thiele et al , 2014; Braig et al , 2017).”
InfluentialZeng, Y., Wang, M., Sun, Z., Sha, L., Yang, J. A., & Li, G. (2021) · Journal of Materials Chemistry B · doi:10.1039/d1tb02192c · Cited by 50
Liu, N., Liu, J., Ji, Y., & Lu, P. (2010) · Life Sciences · doi:10.1016/j.lfs.2010.07.012 · Cited by 54
Singh, U. S., Devaraj, S., & Jialal, I. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.109207 · Cited by 50
C-reactive protein and atherothrombosis: Cause or effect?
Grad, E., & Danenberg, H. D. (2012) · Blood Reviews · doi:10.1016/j.blre.2012.12.001 · Cited by 53
Statin Therapy in Metabolic Syndrome and Hypertension Post-JUPITER: What is the Value of CRP?
Devaraj, S., Siegel, D., & Jialal, I. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-010-0143-2 · Cited by 57
“... transgenic expression of human CRP had no effect on development, progression, or severity of spontaneous atherosclerosis, or on morbidity or mortality, in male apoE-deficient C57BL/6 mice up to 56 weeks, despite deposition of human CRP and mouse complement component 3 in the plaques; again, there was no effect on…”
BackgroundKawahara, K., Biswas, K. K., Unoshima, M., Ito, T., Kikuchi, K., Morimoto, Y., Iwata, M., Tancharoen, S., Oyama, Y., Takenouchi, K., et al. (2007) · Cardiovascular Pathology · doi:10.1016/j.carpath.2007.08.006 · Cited by 49
“Thus, therapeutic inhibition of CRP can represent a new approach to cardiovascular diseases [13].”
BackgroundA review of nutrition and dietary interventions in oncology
Gray, A., Dang, B. N., Moore, T. B., Clemens, R., & Pressman, P. (2020) · SAGE Open Medicine · doi:10.1177/2050312120926877 · Cited by 52
Noveck, R., Stroes, E. S. G., Flaim, J. D., Baker, B. F., Hughes, S., Graham, M. J., Crooke, R. M., & Ridker, P. M. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.001084 · Cited by 48
Evaluating the causal relevance of diverse risk markers: horizontal systematic review
Kuper, H., Nicholson, A., Kivimaki, M., Aitsi-Selmi, A., Cavalleri, G., Deanfield, J. E., Heuschmann, P., Jouven, X., Malyutina, S., Mayosi, B. M., et al. (2009) · BMJ · doi:10.1136/bmj.b4265 · Cited by 48
Amano, T., Matsubara, T., Uetani, T., Kato, M., Kato, B., Yoshida, T., Harada, K., Kumagai, S., Kunimura, A., Shinbo, Y., et al. (2010) · Circulation Journal · doi:10.1253/circj.cj-10-0612 · Cited by 48
Singh, S. K., Suresh, M. V., Prayther, D., Moorman, J. P., Rusiñol, A. E., & Agrawal, A. C. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.6.4316 · Cited by 51
Gu, H., Yang, K., Lin, J., Jing, J., Zhao, X., Wang, Y., Liu, L., Meng, X., Jiang, Y., Li, H., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104054 · Cited by 50
IgM-phosphorylcholine autoantibodies and outcome in acute coronary syndromes
Caidahl, K., Hartford, M., Karlsson, T., Herlitz, J. D., Pettersson, K. S., Fairé, U. D., & Frostegård, J. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.01.018 · Cited by 47
“not only indicate the presence of inflammation but also seem to promote inflammation [4,6,7].”
BackgroundC-reactive protein predicts outcome in COVID-19: is it also a therapeutic target?
Pepys, M. B. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab169 · Cited by 50
“Administration of the inhibitor completely abolished the increased infarct size produced by human CRP in the rat model.(12) The pathogen-”
BackgroundSelf-citationRidker, P. M. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2007.099465 · Cited by 46
Inhibition of Endothelial Nitric Oxide Synthase by C-Reactive Protein: Clinical Relevance
Jialal, I., Verma, S., & Devaraj, S. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.119206 · Cited by 47
Does High C-reactive Protein Concentration Increase Atherosclerosis? The Whitehall II Study
Kivimäki, M., Lawlor, D. A., Davey Smith, G., Kumari, M., Donald, A., Britton, A., Casas, J. P., Shah, T., Brunner, E., Timpson, N. J., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003013 · Cited by 46
“However, much larger analyses using the genetic approach we and others have described, as well as intervention studies involving a new, specific CRPinhibitor [53] are needed to more definitively assess the potential causal role for CRP in atherosclerosis and CHD.”
Das, U. N. (2007) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2007.01.002 · Cited by 48
Role of C-Reactive Protein in Coronary Risk Reduction: Focus on Primary Prevention
Gotto, A. M. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.10.026 · Cited by 50
C-Reactive Protein and Cardiovascular Disease Risk: Still an Unknown Quantity?
Smith, G. D., Timpson, N. J., & Lawlor, D. A. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-1-200607040-00130 · Cited by 47
“Recent evidence suggests that inhibition of the effects of very high levels of human CRP administered to rats undergoing coronary artery ligation–induced myocardial infarction reduces infarct size (19).”
BackgroundA conformational change of C-reactive protein in burn wounds unmasks its proinflammatory properties
Braig, D., Kaiser, B., Thiele, J. R., Bannasch, H., Peter, K., Stark, G. B., Koch, H., & Eisenhardt, S. U. (2014) · International Immunology · doi:10.1093/intimm/dxu056 · Cited by 46
Myocardial inflammation and non-ischaemic heart failure: is there a role for C-reactive protein?
Zimmermann, O., Bienek‐Ziolkowski, M., Wolf, B., Vetter, M., Baur, R., Mailänder, V., Hombach, V., & Torzewski, J. (2009) · Basic Research in Cardiology · doi:10.1007/s00395-009-0026-2 · Cited by 47
“disease [20, 25].”
BackgroundCombination stem cell therapy for heart failure
Ichim, T. E., Solano, F., Lara, F., Rodriguez, J., Cristea, O., Minev, B., Ramos, F., Woods, E. J., Murphy, M. P., Alexandrescu, D. T., et al. (2010) · International Archives of Medicine · doi:10.1186/1755-7682-3-5 · Cited by 45
“tory processes through activation of complement [6,7].”
Prognostic value of admission C-reactive protein in stroke patients undergoing IV thrombolysis
Topakian, R., Strasak, A. M., Nußbaumer, K., Haring, H., & Aichner, F. (2008) · Journal of Neurology · doi:10.1007/s00415-008-0866-y · Cited by 43
“However, if there was clear evidence that high CRP levels adversely affect outcome and exacerbate tissue damage, potential future drugs specifically blocking CRP effects could improve outcome in stroke and acute cardiovascular disease [15].”
BackgroundDitto, A. J., Shah, K. N., Robishaw, N. K., Panzner, M. J., Youngs, W. J., & Yun, Y. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300221f · Cited by 46
Bi, B.-T., Lin, H.-B., Cheng, Y.-F., Zhou, H., Lin, T., Zhang, M.-Z., Li, T.-J., & Xu, J.-P. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2011.12.007 · Cited by 42
“1,6-Bis(phosphocholine)-hexane (bis(PC)-H), a specific small-molecule CRP inhibitor (Pepys et al., 2006), was utilized to further verify the association of CRPwith Ab production, and to initially investigate the regulatory relationship of CRP and Ab.”
BackgroundNovel Cardiac-Specific Biomarkers and the Cardiovascular Continuum
Vassiliadis, E., Barascuk, N., Didangelos, A., & Karsdal, M. A. (2012) · Biomarker Insights · doi:10.4137/bmi.s9536 · Cited by 51
Jones, N. R., Pegues, M. A., McCrory, M. A., Singleton, W., Bethune, C., Baker, B. F., Norris, D. A., Crooke, R. M., Graham, M. J., & Szalai, A. J. (2012) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2012.44 · Cited by 42
Therapeutic Lowering of C-Reactive Protein
Jimenez, R. V., & Szalai, A. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.619564 · Cited by 46
“For example Pepys’ group developed a small molecule inhibitor of CRP (1,6-bis(phosphocholine)-hexane) that they tested in a preclinical rat model (96).”
BackgroundGenetic determinants of C-reactive protein
Danik, J. S., & Ridker, P. M. (2007) · Current Atherosclerosis Reports · doi:10.1007/s11883-007-0019-2 · Cited by 48
“Direct inhibitors of CRP are also currently under investigation [ 20 ].”
BackgroundContribution of Neuroinflammation to the Pathogenesis of Cancer Cachexia
Molfino, A., Gioia, G., Fanelli, F. R., & Laviano, A. (2015) · Mediators of Inflammation · doi:10.1155/2015/801685 · Cited by 42
“Therefore, a potential role for CRP in inflammatory conditions such as cancer could be speculated, in which increased CRP production leads to binding of CRP to exposed ligands in damaged cells, thereby increasing tissue injury [5].”
BackgroundMikolajek, H., Kolstoe, S. E., Pye, V. E., Mangione, P. P., Pepys, M. B., & Wood, S. P. (2011) · Journal of Molecular Recognition · doi:10.1002/jmr.1090 · Cited by 42
“, 2002) and phosphocholine in 1,6-bis [{[(trimethylammonium)ethoxy]phosphinyl}-oxy]hexane, and related bis(phosphocholine)-alkanes, for CRP (Pepys et al., 2006).”
BackgroundInfluentialSelf-citationEffects of Antidiabetic and Antihyperlipidemic Agents on C-Reactive Protein
Dandona, P. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.3.333 · Cited by 45
Dimitrijevic, O., Stojcevski, B. D., Ignjatović, S., & Singh, N. M. (2006) · International Heart Journal · doi:10.1536/ihj.47.833 · Cited by 41
Kruk, M., Przyluski, J., Kalinczuk, L., Pregowski, J., Deptuch, T., Kadziela, J., Bekta, P., Karcz, M., Demkow, M., Chmielak, Z., et al. (2008) · Circulation Journal · doi:10.1253/circj.72.205 · Cited by 41
Young, D. P., Kushner, I., & Samols, D. R. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.4.2420 · Cited by 45
Limiting Myocardial Damage during Acute Myocardial Infarction by Inhibiting C-Reactive Protein
Kitsis, R. N., & Jialal, I. (2006) · New England Journal of Medicine · doi:10.1056/nejmcibr063197 · Cited by 41
Ding, Z., Wei, Y., Peng, J., Wang, S., Chen, G., & Sun, J. (2023) · Biomedicines · doi:10.3390/biomedicines11102711 · Cited by 46
“Various therapeutic agents are being investigated that may alter levels of inflammatory markers, including CRP. 1,6-bis(phosphocholine)-hexane, a specific molecule inhibitor of CRP, was developed to treat CRP-induced cardiovascular disease [139].”
BackgroundSystemic serum amyloid A as a biomarker for exposure to zinc and/or copper-containing metal fumes
Baumann, R., Gube, M., Markert, A., Davatgarbenam, S., Kossack, V., Gerhards, B., Kraus, T., & Brand, P. (2017) · Journal of Exposure Science & Environmental Epidemiology · doi:10.1038/jes.2016.86 · Cited by 41
Quantum capacitance as a reagentless molecular sensing element
Bueno, P. R., Fernandes, F. C. B., & Davis, J. J. (2017) · Nanoscale · doi:10.1039/c7nr06160a · Cited by 44
Feng, Y.-G., He, J., Jiang, L., Chen, D.-N., Wang, A., & Feng, J. (2022) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2022.131518 · Cited by 40
SLEVIN, M. A., & Krupiński, J. (2009) · PubMed · doi:10.14670/hh-24.1473 · Cited by 40
Chen, T.-M., Li, J., Liu, L., Li, F., Li, X.-Y., Wang, Y., Abraham, N. G., & Cao, J. J. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14022684 · Cited by 40
“On the other hand, administration of a CRP inhibitor abrogated the increased infarct size and decreased cardiac dysfunction produced by injection of human CRP [35].”
BackgroundLi, H.-Y., Tang, Z.-M., Wang, Z., Lv, J.-M., Liu, X.-L., Liang, Y.-L., Cheng, B., Gao, N., Ji, S.-R., & Wu, Y. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.09.003 · Cited by 39
Attenuation by Statins of Membrane Raft-Redox Signaling in Coronary Arterial Endothelium
Wei, Y.-M., Li, X., Xiong, J., Abais, J. M., Xia, M., Boini, K. M., Zhang, Y., & Li, P. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.201442 · Cited by 43
Mercurio, V., Lobasso, A., Barbieri, L., Parrella, P., Ciervo, D., Liccardo, B., Bonaduce, D., Tocchetti, C. G., de Paulis, A., & Rossi, F. W. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092154 · Cited by 39
“CRP levels are known to be independent predictors of cardiovascular risk, and contribute directly to the genesis of atherosclerotic lesions [26], determining endothelial dysfunction [27], which is a marker of vascular damage and is a well-known feature of SLE [28].”
BackgroundAnimal Models of C-Reactive Protein
Torzewski, M., Waqar, A. B., & Fan, J. (2014) · Mediators of Inflammation · doi:10.1155/2014/683598 · Cited by 35
“In addition to atherosclerosis, CRP along with complement activation has been shown to acceleratemyocardial infarction in rats and targeting CRP can prevent CRPinducedmyocardial injury [46, 47].”
C-Reactive Protein in Human Atherogenesis: Facts and Fiction
Zimmermann, O., Li, K., Zaczkiewicz, M., Graf, M., Liu, Z., & Torzewski, J. (2014) · Mediators of Inflammation · doi:10.1155/2014/561428 · Cited by 43
“Cross-linking of CRP subunits has been attempted in the past [53].”
BackgroundYuan, Y., Zhu, L., Li, X., Shen, Y., Cao, Y. Y., Fang, X., & Chen, J. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s107279 · Cited by 39
“In addition, a CRP inhibitor has been demonstrated to abrogate the increase in infarct size and cardiac dysfunction caused by CRP injections.(17) Although the use of CRP targeting drugs in cancers has not yet been reported, targeting CRP may offer a therapeutic opportunity since it plays a key role in tumor cell proli…”
Wu, J., Wei, S., Chen, Y., Chen, J., & Luo, S. (2017) · Langmuir · doi:10.1021/acs.langmuir.7b02724 · Cited by 38
Holzknecht, M., Tiller, C., Reindl, M., Lechner, I., Troger, F., Hosp, M., Mayr, A., Brenner, C., Klug, G., Bauer, A., et al. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.06.023 · Cited by 38
Lakshmanakumar, M., Nesakumar, N., Sethuraman, S., Rajan, K. S., Krishnan, U. M., & Rayappan, J. B. B. (2021) · ACS Omega · doi:10.1021/acsomega.1c04043 · Cited by 38
Świątkiewicz, I., Koziński, M., Magielski, P., Fabiszak, T., Sukiennik, A., Navarese, E. P., Odrowąż‐Sypniewska, G., & Kubica, J. (2012) · Mediators of Inflammation · doi:10.1155/2012/250867 · Cited by 38
“CRP binds to phosphocholine groups of necrotic myocardial cell membranes, facilitating complement activation, and thus promoting further inflammatory response, injury of myocardial cells, and expansion of necrosis [23–26].”
BackgroundEisenhardt, S. U., Schmidt, Y., Karaxha, G., Iblher, N., Penna, V., Torio‐Padron, N., Stark, G. B., & Bannasch, H. (2011) · Annals of Plastic Surgery · doi:10.1097/sap.0b013e3181f77ba5 · Cited by 38
“Complement C3 has been identified as mediator of inflammation,(38) especially in combination with C-reactive protein.(36,39,40) In the setting of free flap surgery, this has been recently highlighted by the finding of C3 release from transferred free flap tissue.”
BackgroundC-Reactive Protein in Atherosclerosis—More than a Biomarker, but not Just a Culprit
Kirkgöz, K. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2410297 · Cited by 41
Szalai, A. J., McCrory, M. A., Xing, D., Hage, F. G., Miller, A. C., Oparil, S., Chen, Y.-F., Mazzone, M., EARLY, R. J., Henry, S. P., et al. (2014) · Mediators of Inflammation · doi:10.1155/2014/353614 · Cited by 38
“CRP specific ASOs might pave the way towards a placebo-controlled trial that could clarify the role of CRP in cardiovascular disease.”
BackgroundIshii, H., Toriyama, T., Aoyama, T., Takahashi, H., Amano, T., Hayashi, M., Tanaka, M., Kawamura, Y., Yasuda, Y., Yuzawa, Y., et al. (2009) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.109.889915 · Cited by 37
Lin, C., & Luo, S. (2022) · Langmuir · doi:10.1021/acs.langmuir.2c00448 · Cited by 38
Pepys, M. B., Gallimore, J. R., Lloyd, J., Li, Z., Graham, D., Taylor, G. W., Ellmerich, S., Mangione, P. P., Tennent, G. A., Hutchinson, W. L., et al. (2012) · Journal of Immunological Methods · doi:10.1016/j.jim.2012.07.013 · Cited by 38
Self-citationGao, R., Wang, L., Bai, T., Zhang, Y., Bo, H., & Shu, Y. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.07.010 · Cited by 41
“Compound 1,6-bis PCwas synthesized in SKS Chem according to a previous report (Pepys et al., 2006).”
MethodC-Reactive Protein Promotes the Expansion of Myeloid Derived Cells With Suppressor Functions
Jimenez, R. V., Kuznetsova, V., Connelly, A. N., Hel, Z., & Szalai, A. J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02183 · Cited by 36
“For example, CRP blood levels could be lowered using various available methods such as an antisense-oligonucleotide to CRP (37), smallmolecule inhibitors of CRP (55), or apheresis of CRP (56).”
MethodJabbar, A. S., & Ali, E. T. (2020) · Journal of Environmental and Public Health · doi:10.1155/2020/7693891 · Cited by 41
“that increased CRP production is characteristic of inflammatory, infective, and tissue damage [38].”
BackgroundCastoldi, G., Galimberti, S., Riva, C., Papagna, R., Querci, F., Casati, M., Zerbini, G., Caccianiga, G., Ferrarese, C., Baldoni, M., et al. (2007) · Clinical Science · doi:10.1042/cs20060338 · Cited by 36
“Recently, the same Authors have demonstrated in rats that the administration of a specific CRP inhibitor, blunted the increase in infarct size produced by human CRP injection, indicating that CRP not only might contribute, throught immuno-inflammatory actions, to increase myocardial damage, but also that in this exper…”
BackgroundMajor Depression, C-Reactive Protein, and Incident Ischemic Heart Disease in Healthy Men and Women
Surtees, P. G., Wainwright, N. W. J., Boekholdt, S. M., Luben, R. N., Wareham, N. J., & Khaw, K.-T. (2008) · Psychosomatic Medicine · doi:10.1097/psy.0b013e318183acd5 · Cited by 37
“Recent work suggested that therapeutic inhibition of CRP may provide cardioprotection in acute MI (5).”
BackgroundArbel, Y., Eros, Y., Rogowski, O., Berliner, S. A., Shapira, I., Keren, G., Vered, Y., & Banai, S. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.01.020 · Cited by 36
SERRS immunoassay for quantitative human CRP analysis
Campbell, F., Ingram, A., Monaghan, P., Cooper, J. M., Sattar, N. A., Eckersall, P. D., & Graham, D. (2008) · The Analyst · doi:10.1039/b808087a · Cited by 36
Arsenite activates NFκB through induction of C-reactive protein
Druwe, I. L., Sollome, J. J., Sanchez-Soria, P., Hardwick, R. N., Camenisch, T. D., & Vaillancourt, R. R. (2012) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2012.04.005 · Cited by 39
Role of C-reactive protein in disease progression, diagnosis and management
Ali, S., Zehra, A., Khalid, M. U., Hassan, M., & Shah, S. I. A. (2023) · Discoveries · doi:10.15190/d.2023.18 · Cited by 47
Biomimetic Interfaces Reveal Activation Dynamics of C‐Reactive Protein in Local Microenvironments
Goda, T., Kjäll, P., Ishihara, K., Richter‐Dahlfors, A., & Miyahara, Y. (2014) · Advanced Healthcare Materials · doi:10.1002/adhm.201300625 · Cited by 38
CRP velocity and short-term mortality in ST segment elevation myocardial infarction
Milwidsky, A., Ziv‐Baran, T., Letourneau-Shesaf, S., Keren, G., Taieb, P., Berliner, S. A., & Shacham, Y. (2017) · Biomarkers · doi:10.1080/1354750x.2017.1279218 · Cited by 35
“Therapeutic inhibition and apheresis of CRP was found to be an effective approach to cardio-protection in acute myocardial infarction in rat and pig models (15,16).”
BackgroundComplement in ischaemia–reperfusion injury and transplantation
Howard, M. C., Nauser, C. L., Farrar, C. A., & Sacks, S. H. (2021) · Seminars in Immunopathology · doi:10.1007/s00281-021-00896-3 · Cited by 39
“Addition of human CRP to rats in a myocardial IRI model increased the resulting infarct size [17] and the addition of a CRP inhibitor resulted in the inverse [18, 19], demonstrating a role for C1q and by inference the classical pathway.”
BackgroundDimitrov, J. D., Roumenina, L. T., Doltchinkova, V. R., & Vassilev, T. L. (2007) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2006.01893.x · Cited by 36
The Role and Clinical Significance of High-Sensitivity C-Reactive Protein in Cardiovascular Disease
Seo, H. S. (2012) · Korean Circulation Journal · doi:10.4070/kcj.2012.42.3.151 · Cited by 35
Brummett, B. H., Babyak, M. A., Singh, A., Jiang, R., Williams, R. B., Harris, K. M., & Siegler, I. C. (2013) · Psychosomatic Medicine · doi:10.1097/psy.0000000000000005 · Cited by 38
“Although a causal role has not been definitively established for inflammation with respect to CVD, some have posited that intervening to reduce CRP levels may, in turn, reduce the risk of myocardial infarction (12).”
BackgroundLectin-like Oxidized LDL Receptor 1 Is Involved in CRP-Mediated Complement Activation
Fujita, Y., Yamaguchi, S., Kakino, A., Iwamoto, S., Yoshimoto, R., & Sawamura, T. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2011.168625 · Cited by 36
Koopmans, S. J., Dekker, R. A., Ackermans, M. T., Sauerwein, H. P., Serlie, M. J. M., van Beusekom, H. M., van den Heuvel, M., & van der Giessen, W. J. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-64 · Cited by 40
“It seems therefore that postprandial CRP concentrations, which were increased 2-fold compared to fasting concentrations, react strongly to vascular damage and/or atherosclerosis [41].”
Xi, H., He, W., Liu, Q., & Chen, Z. (2018) · ACS Sustainable Chemistry & Engineering · doi:10.1021/acssuschemeng.8b02063 · Cited by 34
Biomimetic Polymer-Based Method for Selective Capture of C-Reactive Protein in Biological Fluids
Wang, Q., Jin, H., Xia, D., Shao, H., Peng, K., Liu, X., Huang, H., Zhang, Q., Guo, J., Wang, Y., et al. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b15581 · Cited by 34
Yang, J., Wang, J., Zhu, S., Chen, X., Wu, H., Yang, D., & Zhang, J. (2007) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-007-9683-3 · Cited by 37
“Recently, therapeutic inhibition of CRP has been shown to be a promising new approach to cardioprotection in acute myocardial infarction in rat models, which indicates that CRP may play an important role in the progression of cardiac dysfunction [16].”
BackgroundResultCardoso, C. R. L., Leite, N. C., & Salles, G. F. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.004554 · Cited by 36
C-reactive protein is neither a marker nor a mediator of atherosclerosis
Pepys, M. B. (2008) · Nature Reviews Nephrology · doi:10.1038/ncpneph0778 · Cited by 34
Self-citationResearch Progress of Myocardial Fibrosis and Atrial Fibrillation
Li, G., Yang, J., Zhang, D., Wang, X., Han, J., & Guo, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.889706 · Cited by 39
“Studies have shown that C-reactive protein induce cardiac injury through inflammatory reaction and serum complement activation (38).”
BackgroundIshii, H., Aoyama, T., Takahashi, H., Kamoi, D., Tanaka, M., Yoshikawa, D., Hayashi, M., Matsubara, T., & Murohara, T. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.11.034 · Cited by 33
Frenkel, D., Pachori, A. S., Zhang, L., Dembinsky‐Vaknin, A., Farfara, D., Petrovic-Stojkovic, S., Dzau, V. J., & Weiner, H. L. (2009) · International Immunology · doi:10.1093/intimm/dxp051 · Cited by 33
The relationship between hs-CRP and asthma control test in asthmatic patients
Kılıç, H., Karalezli, A., Hasanoğlu, H. C., Erel, Ö., & Ateş, C. (2012) · Allergologia et Immunopathologia · doi:10.1016/j.aller.2011.10.002 · Cited by 38
The Inflammatory Hypothesis: Any Progress in Risk Stratification and Therapeutic Targets?
Blankenberg, S., & Yusuf, S. (2006) · Circulation · doi:10.1161/circulationaha.106.652081 · Cited by 38
C-reactive protein promotes diabetic kidney disease via Smad3-mediated NLRP3 inflammasome activation
Wang, Y., You, Y., Guo, J., Wang, J., Shao, B., Li, H.-D., Meng, X., Lan, H.-Y., & Chen, H. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.11.018 · Cited by 36
“61 However, the use of ASO treatment is controversial as one type of ASO has been found to increase IL-6 and CRP levels in healthy volunteers.”
Resistin Is More Abundant in Liver Than Adipose Tissue and Is Not Up-Regulated by Lipopolysaccharide
Szalowska, E., Elferink, M. G. L., Hoek, A., Groothuis, G. M. M., & Vonk, R. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2787 · Cited by 36
Metadata
- Authors
- Pepys, M. B., Hirschfield, G. M., Tennent, G. A., Ruth Gallimore, J., Kahan, M. C., Bellotti, V., Hawkins, P. N., Myers, R. M., Smith, M. D., Polara, A., Cobb, A. J. A., Ley, S. V., Andrew Aquilina, J., Robinson, C. V., Sharif, I., Gray, G. A., Sabin, C. A., Jenvey, M. C., Kolstoe, S. E., Thompson, D., & Wood, S. P.
- Affiliations
- The Royal Free Hospital (GB)
- University of Pavia (IT)
- University of Cambridge (GB)
- University of Edinburgh (GB)
- University of Southampton (GB)
- University of Sussex (GB)
- Corresponding author
- Pepys, Mark B.
- ORCID
- Venue
- Nature
- Published
- 2006-04
- Volume
- 440
- Issue
- 7088
- Pages
- 1217-1221
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2080883999
- Cited by
- 672
- References
- 31
- Citations by year
- 2026: 6 · 2025: 17 · 2024: 19 · 2023: 30 · 2022: 27 · 2021: 28 · 2020: 32 · 2019: 21 · 2018: 23 · 2017: 20 · 2016: 23 · 2015: 16 · 2014: 35 · 2013: 30 · 2012: 40
- FWCI
- 26.49
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- CentAUR (University of Reading) (acceptedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- Research Online (University of Wollongong) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Figshare (submittedVersion)
- Funders
- Wellcome Trust
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Biomarkers in Disease Mechanisms
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- C-reactive protein, acute myocardial infarction, complement activation, cardioprotection, infarct size, neuroprotection, cerebral ischemia, small-molecule drug design, acute phase proteins, inflammation, stroke, drug repurposing
- MeSH terms
- Animals, C-Reactive Protein, Cardiovascular Diseases, Complement System Proteins, Hexanes, Humans, Male, Models, Molecular, Molecular Conformation, Myocardial Infarction, Phosphorylcholine, Drug Design, Rats, Wistar, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.